Clinical Trial Update: Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a triple combination of zanubrutinib, obinutuzumab, and lenalidomide in newly diagnosed chronic lymphocytic leukemia/small lymphocytic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Obinutuzumab (obinutuzumab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING